#GynCSM Transcript
Healthcare social media transcript of the #GynCSM hashtag.
โ ().
See #GynCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats #UterineCancer is the most common #cancer of the female reproductive system. Learn more here: https://t.co/vmRb0W9SNC #GynCSM https://t.co/lXzCAqr7RF |
 | GYN Cancer | #GYNCSM @gyncsm Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | Dee Sparacio @womenofteal RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
| GYN Cancer | #GYNCSM @gyncsm Our co-moderators are @womenofteal @btrfly12 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We start out with brief introโs - Please take a moment to introduce yourself. :) #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We start out with brief introโs - Please take a moment to introduce yourself. :) #gyncsm |
 | T @trishaannete RT @NCICancerStats: #UterineCancer is the most common #cancer of the female reproductive system. Learn more here: #UterineCancer is the most common #cancer of the female reproductive system. Learn more here: https://t.co/vmRb0W9SNC #GynCSM https://t.co/lXzCAqr7RF |
| Dee Sparacio @womenofteal Dee here! Dx #ovca HGSOC Stage3B 2005, OC research advocate, blogger & co-moderator #gyncsm |
 | Shereese Maynard, MS; MBA ๐ท She/Her @ShereeseMayMba Hello all. I'm Shereese. I'll be lurking while working tonight. #gyncsm https://t.co/4QzuuU9AUO |
 | Christina Lizaso @btrfly12 Hi all. I'm Christina Lizaso โ passionate re: community engagement and cancer. Iโll be moderating as @gyncsm today. #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Hello #gyncsm group! Iโm Ronny Drapkin โ a physician-scientist at @Penn @PennCancer, director of @Penn_OCRC, and director of gyn cancer research @BasserBRCA. Excited to be here! |
| Dee Sparacio @womenofteal @ShereesePubHlth Thanks for joining us tonight Shereese! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. |
| Dee Sparacio @womenofteal We hope you will take a minute to view this video by @ronny_drapkin which explains BRCA and ovarian cancer https://t.co/ArsKLLZixW #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Pls continue intro's & welcomes - we'll start in w/ the "ground rules" :) and tips! #gyncsm |
 | Erica Bednar @EMBOSU Hi everyone-excited to join tonight after many missed chats the past several months! I'm Erica, genetic counselor in the Gyn Onc clinics at @MDAndersonNews and @harrishealth LBJ hospital #gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: We hope you will take a minute to view this video by @ronny_drapkin which explains BRCA and ovarian cancer https://t.co/ArsKLLZixW #gyncsm |
| Dee Sparacio @womenofteal @EMBOSU @MDAndersonNews @harrishealth Hi Erica-- so glad you can join us tonight. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
 | Lisa M Guzzardi, RN @LguzzardiM Greetings from NY! Patient advocate & curator of #hereditarycancer journal club here. #gyncsm |
| Dee Sparacio @womenofteal #gyncsm tagged resources and referrals are not a substitute for speaking with your doctor who understands your needs and history. |
| Dee Sparacio @womenofteal @LguzzardiM Hi Lisa - Thanks for joining us tonight and for Facebook journal club. I learn from it all the time. #gyncsm |
| Dee Sparacio @womenofteal Remember- Twitter is an open social network & posts are public.Use a Direct Messages to exchange email addresses/personal info #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Are you new to tweet chats? Follow hashtag #gyncsm and include it in every tweet during the next hour to engage with others about our topic. |
 | Michele Rhee @michelerhee @gyncsm Hello! Itโs Michele from Boston. Diagnosed with thyroid cancer at 20 & general #AYACancer/#AYACSM & #RareDisease/#RareCancer patient advocate. #gyncsm https://t.co/GEzw94anw3 |
| Dee Sparacio @womenofteal @michelerhee @gyncsm Welcome Michele Thanks so much for joining in.#gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM @womenofteal Pleasure is all mine, your #gyncsm advocacy is deeply admired. |
| GYN Cancer | #GYNCSM @gyncsm So happy to have @ronny_drapkin joining us tonight to discuss his research on where and how high-grade serous ovarian cancer originates. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: So happy to have @ronny_drapkin joining us tonight to discuss his research on where and how high-grade serous ovarian cancer originates. #gyncsm |
 | Catherine Gegaris @cgegaris1 @gyncsm #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We also welcome all those โlistening inโ. You can always tweet us or email us with questions/comments after the chat is over. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Thanks for the invite. Excited to be here! #gyncsm |
| Dee Sparacio @womenofteal Thank you to all who have tweeted during the past month with the #gyncsm hashtag and especially those who RT'd about this chat. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Tonight on #gyncsm we are discussing research into the origin of high-grade serous ovarian cancer. Moderator note: weโll be using HGSOC during this #gyncsm chat to stand for high-grade serous ovarian cancer. |
 | Amanda Crowell Itliong @MIShouldTalk Hey #gyncsm crew! Iโm Amanda from MI. Patient and advocate with low grade ovarian cancer and always looking to learn more about all cancers |
| Dee Sparacio @womenofteal @MIShouldTalk Great to have you Amanda ! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Weโll use a Topic format with T1:, T2:, etc. posed from this handle. Include the corresponding T1:, T2:, etc. at the front of your answer/comment. There are 5 Topic questions tonight followed by a Today I Learned (TIL) segment. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Weโll use a Topic format with T1:, T2:, etc. posed from this handle. Include the corresponding T1:, T2:, etc. at the front of your answer/comment. There are 5 Topic questions tonight followed by a Today I Learned (TIL) segment. #gyncsm |
| Erica Bednar @EMBOSU RT @gyncsm: Tonight on #gyncsm we are discussing research into the origin of high-grade serous ovarian cancer. Moderator note: weโll be using HGSOC during this #gyncsm chat to stand for high-grade serous ovarian cancer. |
| GYN Cancer | #GYNCSM @gyncsm You can find a list of the upcoming topic questions on our #gyncsm blog page: https://t.co/q3ZnHiAGvI |
| Dee Sparacio @womenofteal RT @gyncsm: You can find a list of the upcoming topic questions on our #gyncsm blog page: You can find a list of the upcoming topic questions on our #gyncsm blog page: https://t.co/q3ZnHiAGvI |
| Christina Lizaso @btrfly12 RT @gyncsm: You can find a list of the upcoming topic questions on our #gyncsm blog page: You can find a list of the upcoming topic questions on our #gyncsm blog page: https://t.co/q3ZnHiAGvI |
| GYN Cancer | #GYNCSM @gyncsm Before we dive into the topics, @ronny_drapkin, can you share a little bit about what led you to study ovarian cancer and also a little about your lab in terms of its size and research focus? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Before we dive into the topics, @ronny_drapkin, can you share a little bit about what led you to study ovarian cancer and also a little about your lab in terms of its size and research focus? #gyncsm |
| Dee Sparacio @womenofteal Welcome @cawincolumbia and @cgregaris ! Thanks for joining us. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Iโll reply with points 1 (1/2): When I was a postdoc @DanaFarber, I worked in a lab that focused on the function of BRCA1. However, most of the effort was in breast cancer but I knew that BRCA1 was a tumor-suppressor for both ovarian and breast cancers. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin (2/2) My mentor, David Livingston, gave me the latitude to do research in ovarian cancer and I began by focusing on a biomarker for early detection and thinking about pathogenesis. #gyncsm |
| Michele Rhee @michelerhee @womenofteal @gyncsm Iโm so happy I could make it this week! #gyncsm https://t.co/NtwddEeXhs |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: Iโll reply with points 1 (1/2): Iโll reply with points 1 (1/2): When I was a postdoc @DanaFarber, I worked in a lab that focused on the function of BRCA1. However, most of the effort was in breast cancer but I knew that BRCA1 was a tumor-suppressor for both ovarian and breast cancers. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: (2/2) My mentor, David Livingston, gave me the latitude to do research in ovarian cancer and I began by focusing on a biomarker for early detection and thinking about pathogenesis. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Of the 4 main OC types, most #ovariancancer (85-90%) falls into the Epithelial type. High-grade serous (HGSOC) is the most common subtype of ovarian cancer, making up ~75% of Epithelial ovarian cancer, which includes fallopian tube cancer and primary peritoneal cancer. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Of the 4 main OC types, most #ovariancancer (85-90%) falls into the Epithelial type. High-grade serous (HGSOC) is the most common subtype of ovarian cancer, making up ~75% of Epithelial ovarian cancer, which includes fallopian tube cancer and primary peritoneal cancer. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Here comes Topic 1 (T1:)... #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin My lab is made up of students, postdoctoral fellows, and physician-scientists. There are about 7-10 people in the lab at any one time. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: My lab is made up of students, postdoctoral fellows, and physician-scientists. There are about 7-10 people in the lab at any one time. #gyncsm |
| Erica Bednar @EMBOSU RT @gyncsm: Of the 4 main OC types, most #ovariancancer (85-90%) falls into the Epithelial type. High-grade serous (HGSOC) is the most common subtype of ovarian cancer, making up ~75% of Epithelial ovarian cancer, which includes fallopian tube cancer and primary peritoneal cancer. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T1: What makes HGSOC different from other sub-types in terms of the tumor itself, how it spreads, how it is treated, and its prognosis? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T1: T1: What makes HGSOC different from other sub-types in terms of the tumor itself, how it spreads, how it is treated, and its prognosis? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 1 (1/2): HGSOC is the most common subtype of ovarian cancer. Unfortunately, it tends to spread before detection. Once it is diagnosed, most patients get treated with surgery and chemotherapy. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 2 (2/2): Initially, the majority of patients will have a positive response to the treatment. Unfortunately, most will have their tumors come back. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 1 (1/2): Point 1 (1/2): HGSOC is the most common subtype of ovarian cancer. Unfortunately, it tends to spread before detection. Once it is diagnosed, most patients get treated with surgery and chemotherapy. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 2 (2/2): Point 2 (2/2): Initially, the majority of patients will have a positive response to the treatment. Unfortunately, most will have their tumors come back. #gyncsm |
 | Dawn Ford @tealbtrflies4me RT @gyncsm: Tonight on #gyncsm we are discussing research into the origin of high-grade serous ovarian cancer. Moderator note: weโll be using HGSOC during this #gyncsm chat to stand for high-grade serous ovarian cancer. |
| Lisa M Guzzardi, RN @LguzzardiM RT @gyncsm: Of the 4 main OC types, most #ovariancancer (85-90%) falls into the Epithelial type. High-grade serous (HGSOC) is the most common subtype of ovarian cancer, making up ~75% of Epithelial ovarian cancer, which includes fallopian tube cancer and primary peritoneal cancer. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T2: When did research start pointing to the fallopian tubes as the origin site of HGSOC? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T2: T2: When did research start pointing to the fallopian tubes as the origin site of HGSOC? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 1 (1/4): After the BRCA genes were cloned in the mid-1990s, we began offering women at risk prophylactic surgery. That included mastectomy for breast cancer and removal of the ovaries (and fallopian tubes) for ovarian cancer. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 1 (1/4): Point 1 (1/4): After the BRCA genes were cloned in the mid-1990s, we began offering women at risk prophylactic surgery. That included mastectomy for breast cancer and removal of the ovaries (and fallopian tubes) for ovarian cancer. #gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM @ronny_drapkin Due to often late staged diagnosis, is that correct @ronny_drapkin ? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 2 (2/4): The removal of the FTs along with the ovaries was surgically convenient and most of the attention was placed on the ovary. As early as 2000, reports began to emerge that some of these prophylactic specimens had abnormal looking cells in the FT. #gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM RT @ronny_drapkin: Point 2 (2/4): Point 2 (2/4): The removal of the FTs along with the ovaries was surgically convenient and most of the attention was placed on the ovary. As early as 2000, reports began to emerge that some of these prophylactic specimens had abnormal looking cells in the FT. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @LguzzardiM #gyncsm Yes, diagnosis is often late stage when tumor has metastasized. |
| Dee Sparacio @womenofteal FT = Fallopian Tubes HGSOC= High Grade Serous Ovarian Cancer #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 2 (2/4): Point 2 (2/4): The removal of the FTs along with the ovaries was surgically convenient and most of the attention was placed on the ovary. As early as 2000, reports began to emerge that some of these prophylactic specimens had abnormal looking cells in the FT. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 3 (3/4): Around 2005-2006, Dr. Chris Crum (my clinical mentor during residency) @BrighamWomens developed the SEE-FIM (Sectioning and Extensively Examining the FIMbriated end of the fallopian tube) protocol to get a better understanding of what was happening there. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 4 (4/4): That is when we realized that most of these tumors were arising from the tube rather than the ovary. Subsequent use of SEE-FIM confirmed this in publications around the world. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 3 (3/4): Point 3 (3/4): Around 2005-2006, Dr. Chris Crum (my clinical mentor during residency) @BrighamWomens developed the SEE-FIM (Sectioning and Extensively Examining the FIMbriated end of the fallopian tube) protocol to get a better understanding of what was happening there. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 4 (4/4): Point 4 (4/4): That is when we realized that most of these tumors were arising from the tube rather than the ovary. Subsequent use of SEE-FIM confirmed this in publications around the world. #gyncsm |
| Christina Lizaso @btrfly12 T2: The first I heard about the fallopian tube as possible origin site for #ovariancancer was around 2010 I think... so thinking the studies are maturing and diving deeper and starting to influence practice.... #gyncsm |
| Dee Sparacio @womenofteal The development of SEE-FIM protocol was crucial to your research. I saw that a Team in Thailand recently confirmed benefit of its use. https://t.co/hPdUU1IGb0 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3: What characteristics did you study when you examined fallopian tube lesions versus lesions of the ovary? How are BRCA mutations involved? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @btrfly12 #gyncsm In retrospect, the earliest published studies were in 2000-2001. It wasn't until after SEE-FIM that we realized what was happening and appreciated those earlier studies. |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: @btrfly12 #gyncsm In retrospect, the earliest published studies were in 2000-2001. It wasn't until after SEE-FIM that we realized what was happening and appreciated those earlier studies. |
 | Sarah Temkin @temkins The majority of #ovariancancer is diagnosed at Stage III or IV. To date a mode of screening or early detection which decreases #cancermortality has not been identified. This is why prevention is so important to this disease. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Iโll start my reply with point 1 (1/6): Much of that data is based on histological studies. We wanted to see if we could definitively show that these tumors arise from precursor lesions in the FTs by using next generation sequencing and advanced bioinformatic tools. #gyncsm |
 | Kristel Gonzalez @Kristel_GT RT @EMBOSU: Hi everyone-excited to join tonight after many missed chats the past several months! I'm Erica, genetic counselor in the Gyn Onc clinics at @MDAndersonNews and @harrishealth LBJ hospital #gyncsm |
| Dee Sparacio @womenofteal @ronny_drapkin Curious Is SEE-FIM protocol freely available to all researchers around the world? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T3: T3: What characteristics did you study when you examined fallopian tube lesions versus lesions of the ovary? How are BRCA mutations involved? #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Iโll start my reply with point 1 (1/6): Iโll start my reply with point 1 (1/6): Much of that data is based on histological studies. We wanted to see if we could definitively show that these tumors arise from precursor lesions in the FTs by using next generation sequencing and advanced bioinformatic tools. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 2 (2/6): We identified cases of HGSOC that had precursors identified in the FT by pathologists. We then used laser-capture microdissection to carefully isolate those cells and applied whole-exome sequencing to characterize the mutations and copy number changes. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 2 (2/6): Point 2 (2/6): We identified cases of HGSOC that had precursors identified in the FT by pathologists. We then used laser-capture microdissection to carefully isolate those cells and applied whole-exome sequencing to characterize the mutations and copy number changes. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @womenofteal #gyncsm It is a simple procedure done in the Pathology department when prophylactic specimens are examined and processed for microscopic evaluation. |
| Michele Rhee @michelerhee @temkins What are the recommendations for prevention of #ovariancancer? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 3 (3/6): These efforts revealed that mutations in p53 are among the earliest defects detectable. We also found that copy number alterations (amplifications or deletions in certain genes or chromosomal regions) are also frequent, early, and involve the BRCA genes. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 3 (3/6): Point 3 (3/6): These efforts revealed that mutations in p53 are among the earliest defects detectable. We also found that copy number alterations (amplifications or deletions in certain genes or chromosomal regions) are also frequent, early, and involve the BRCA genes. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 4 (4/6): As lesions become more complex they retain the early defects (p53 mutations and copy number changes) and acquire additional ones. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm moderator note: just a reminder we are using HGSOC as abbreviation for High-Grade Serous Ovarian Cancer |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 5 (5/6): Using computational tools we were able to develop a molecular clock. This approach showed that there are 6-7 years between the development of a precursor lesion (called a STIC) and clinically evident 'ovarian' cancer. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 4 (4/6): Point 4 (4/6): As lesions become more complex they retain the early defects (p53 mutations and copy number changes) and acquire additional ones. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 6 (6/6): However, once the tumor cells get to the ovary, there are only 1.9 years before they spread to the rest of the abdominal cavity. Hence, the window of opportunity to intervene is the 6-7 years before the cells get to the ovary. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 5 (5/6): Point 5 (5/6): Using computational tools we were able to develop a molecular clock. This approach showed that there are 6-7 years between the development of a precursor lesion (called a STIC) and clinically evident 'ovarian' cancer. #gyncsm |
| Erica Bednar @EMBOSU This is one of my favorite diagrams to help visually understand how the fallopian tube may be involved in HGSOC development #gyncsm (From article by @MDAndersonNews colleagues https://t.co/IDr3dbcDae) https://t.co/DDu6TxwXy4 |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 6 (6/6): Point 6 (6/6): However, once the tumor cells get to the ovary, there are only 1.9 years before they spread to the rest of the abdominal cavity. Hence, the window of opportunity to intervene is the 6-7 years before the cells get to the ovary. #gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM Whatโs new in biomarker testing for #ovariancancer? #gyncsm #womenshealth #genetics #earlydetection https://t.co/fysMPyh7wF |
| Dee Sparacio @womenofteal RT @EMBOSU: This is one of my favorite diagrams to help visually understand how the fallopian tube may be involved in HGSOC development #gyncsm (From article by @MDAndersonNews colleagues https://t.co/IDr3dbcDae) https://t.co/DDu6TxwXy4 |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @michelerhee @temkins #gyncsm we'll get to that shortly! |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @temkins #gyncsm Correct. More on that shortly. |
| Dee Sparacio @womenofteal @ronny_drapkin I often wondered how long from those first precancerous cells it took to develop into cancer. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: Point 6 (6/6): Point 6 (6/6): However, once the tumor cells get to the ovary, there are only 1.9 years before they spread to the rest of the abdominal cavity. Hence, the window of opportunity to intervene is the 6-7 years before the cells get to the ovary. #gyncsm |
| Christina Lizaso @btrfly12 RT @EMBOSU: This is one of my favorite diagrams to help visually understand how the fallopian tube may be involved in HGSOC development #gyncsm (From article by @MDAndersonNews colleagues https://t.co/IDr3dbcDae) https://t.co/DDu6TxwXy4 |
| Christina Lizaso @btrfly12 Love the idea of finding a way to catch the pre-cancerous cells like we can already do in #cervicalcancer #gyncsm |
| Dee Sparacio @womenofteal @btrfly12 Me too! #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin This is what the SEE-FIM protocol looks like (after a pathologist processes the FT) #gyncsm https://t.co/8kvPXBwQeC |
| GYN Cancer | #GYNCSM @gyncsm T4a: Are HGSOC cancer cells found in the fallopian tube different than those found in/on the ovary? How do they differ from Fallopian Tube Cancer cells? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @btrfly12 #gyncsm Yes! |
| Dee Sparacio @womenofteal RT @ronny_drapkin: This is what the SEE-FIM protocol looks like (after a pathologist processes the FT) #gyncsm https://t.co/8kvPXBwQeC |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm moderator note: and we are using FT for Fallopian Tube |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin This is what the FT precursors look like #gyncsm https://t.co/6YNO16pYx7 |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T4: While there have been many efforts to find early cancer cells in/on the ovary, no one has been able to reproducibly identify them. Since SEE-FIM, a number of systematic attempts have tried to find early precursors in the ovary but have failed. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: #gyncsm moderator note: and we are using FT for Fallopian Tube |
| Dee Sparacio @womenofteal RT @ronny_drapkin: This is what the FT precursors look like #gyncsm https://t.co/6YNO16pYx7 |
| GYN Cancer | #GYNCSM @gyncsm T4b: Patients/survivors/others - Have your (or someone's you are involved w/) pathology reports shown cancer cells in the fallopian tubes? #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: T4: T4: While there have been many efforts to find early cancer cells in/on the ovary, no one has been able to reproducibly identify them. Since SEE-FIM, a number of systematic attempts have tried to find early precursors in the ovary but have failed. #gyncsm |
| Michele Rhee @michelerhee @womenofteal @btrfly12 Yes!! Earlier diagnosis matters. If people arenโt diagnosed until disease has progressed to a late stage, then *of course* itโs so much harder to treat. #gyncsm |
 | mary @zebrafinch RT @gyncsm: You can find a list of the upcoming topic questions on our #gyncsm blog page: You can find a list of the upcoming topic questions on our #gyncsm blog page: https://t.co/q3ZnHiAGvI |
| mary @zebrafinch RT @gyncsm: Tonight on #gyncsm we are discussing research into the origin of high-grade serous ovarian cancer. Moderator note: weโll be using HGSOC during this #gyncsm chat to stand for high-grade serous ovarian cancer. |
| Dee Sparacio @womenofteal @gyncsm My pathology report did not show cancer in my FT but I wonder if they were examined with SEE-FIM if cancer cells would be found. Dx 2005 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm About to move into our last general topic area - with 3 sub-questions... #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @gyncsm #gyncsm I know that @Penn and @BrighamWomens the pathology reports include the mention of 'serous tubal intraepithelial carcinoma' (STIC) if they see the lesion in the FT. |
| mary @zebrafinch RT @gyncsm: We also welcome all those โlistening inโ. You can always tweet us or email us with questions/comments after the chat is over. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: @gyncsm #gyncsm I know that @Penn and @BrighamWomens the pathology reports include the mention of 'serous tubal intraepithelial carcinoma' (STIC) if they see the lesion in the FT. |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @womenofteal @gyncsm #gyncsm Probably not. The SEE-FIM paper was published in 2007. |
| GYN Cancer | #GYNCSM @gyncsm T5: As we look to the future: How will knowledge of where a majority of ovarian cancers originate impact women at increased risk? How might this research help in the development of an early detection test? What is the impact for women diagnosed with ovarian cancer? #gyncsm |
| Shereese Maynard, MS; MBA ๐ท She/Her @ShereeseMayMba RT @ronny_drapkin: @womenofteal @gyncsm #gyncsm Probably not. The SEE-FIM paper was published in 2007. |
| Dee Sparacio @womenofteal RT @gyncsm: T5: T5: As we look to the future: How will knowledge of where a majority of ovarian cancers originate impact women at increased risk? How might this research help in the development of an early detection test? What is the impact for women diagnosed with ovarian cancer? #gyncsm |
| Shereese Maynard, MS; MBA ๐ท She/Her @ShereeseMayMba RT @gyncsm: About to move into our last general topic area - with 3 sub-questions... #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T5: Iโll answer with a few points (1/4): Tremendous potential here! The most obvious areas will be in prevention and early detection. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 2 (2/4): The significant morbidity associated with removal of the FTs and ovaries (surgical menopause) has led up to 30-40% of BRCA carriers to delay or refuse risk-reducing surgery. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: T5: Iโll answer with a few points (1/4): T5: Iโll answer with a few points (1/4): Tremendous potential here! The most obvious areas will be in prevention and early detection. #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: T5: T5: As we look to the future: How will knowledge of where a majority of ovarian cancers originate impact women at increased risk? How might this research help in the development of an early detection test? What is the impact for women diagnosed with ovarian cancer? #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 2 (2/4): Point 2 (2/4): The significant morbidity associated with removal of the FTs and ovaries (surgical menopause) has led up to 30-40% of BRCA carriers to delay or refuse risk-reducing surgery. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 3 (3/4): For these women, there are ongoing studies looking at the effect of removing the FTs first (interval salpingectomy) and later removing the ovaries (delayed oophorectomy). One example is the WISP study by @KarenLuMD #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 3 (3/4): Point 3 (3/4): For these women, there are ongoing studies looking at the effect of removing the FTs first (interval salpingectomy) and later removing the ovaries (delayed oophorectomy). One example is the WISP study by @KarenLuMD #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Point 4 (4/4): For average risk women there is โopportunistic salpingectomyโ - for example, if you are having a hysterectomy for any reason, the rec is to remove the FTs #gyncsm |
| Erica Bednar @EMBOSU @ronny_drapkin @gyncsm @Penn @BrighamWomens I've seen a few reports at MD Anderson where we have detected STIC...always very interesting especially since most women are diagnosed with HGSOC at an advanced stage, we rarely have the chance to see such an early presentation of FT/HGSOC #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: Point 2 (2/4): Point 2 (2/4): The significant morbidity associated with removal of the FTs and ovaries (surgical menopause) has led up to 30-40% of BRCA carriers to delay or refuse risk-reducing surgery. #gyncsm |
| Sarah Temkin @temkins A5: For patients it's important to know that ovarian, fallopian tube and primary peritoneal high grade serous cancers are considered the same disease for the purpose of treatment #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: Point 3 (3/4): Point 3 (3/4): For these women, there are ongoing studies looking at the effect of removing the FTs first (interval salpingectomy) and later removing the ovaries (delayed oophorectomy). One example is the WISP study by @KarenLuMD #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: Point 4 (4/4): Point 4 (4/4): For average risk women there is โopportunistic salpingectomyโ - for example, if you are having a hysterectomy for any reason, the rec is to remove the FTs #gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM @gyncsm Iโve seen a few #BRCA + women who had a risk โฌ๏ธ BSO with path reports revealing early staged Fallopian tube cancers. Life saving surgery indeed! @ronny_drapkin do you know if somatic testing has revealed other mutations ? Is this being done? Inquiring minds wanna know #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: Point 4 (4/4): Point 4 (4/4): For average risk women there is โopportunistic salpingectomyโ - for example, if you are having a hysterectomy for any reason, the rec is to remove the FTs #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: A5: A5: For patients it's important to know that ovarian, fallopian tube and primary peritoneal high grade serous cancers are considered the same disease for the purpose of treatment #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: A5: A5: For patients it's important to know that ovarian, fallopian tube and primary peritoneal high grade serous cancers are considered the same disease for the purpose of treatment #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @EMBOSU @gyncsm @Penn @BrighamWomens #gyncsm STIC 'in isolation' are only likely to be seen in BRCA1/2 mutation carriers. The frequency of identifying a STIC-alone (no HGSOC) is ~4-5% of RRSOs |
| Dee Sparacio @womenofteal @ronny_drapkin @gyncsm How are BRCA and other mutations involved in these FT lesions? #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: @EMBOSU @gyncsm @Penn @BrighamWomens #gyncsm STIC 'in isolation' are only likely to be seen in BRCA1/2 mutation carriers. The frequency of identifying a STIC-alone (no HGSOC) is ~4-5% of RRSOs |
| Michele Rhee @michelerhee @ronny_drapkin For average or low risk women, is there anything other than opportunistic FT removal as a preventative measure re: #ovariancancer? #gyncsm |
| Lisa M Guzzardi, RN @LguzzardiM RT @ronny_drapkin: @EMBOSU @gyncsm @Penn @BrighamWomens #gyncsm STIC 'in isolation' are only likely to be seen in BRCA1/2 mutation carriers. The frequency of identifying a STIC-alone (no HGSOC) is ~4-5% of RRSOs |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @LguzzardiM @gyncsm #gyncsm Yes. First, all women with HGSOC are now recommended for testing. Second, in addition to BRCA1 and BRCA2 there are other genes, like RAD51C, that are associated with risk. We don't know as much about these genes though. |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @temkins #gyncsm Indeed - pathologically, they are the same disease too! |
| Erica Bednar @EMBOSU Learn more about WISP here: https://t.co/rSkggrXgJb #gyncsm #gencsm #BRCA #LynchSyndrome #HereditaryCancer #previvors |
| Lisa M Guzzardi, RN @LguzzardiM RT @ronny_drapkin: @LguzzardiM @gyncsm #gyncsm Yes. First, all women with HGSOC are now recommended for testing. Second, in addition to BRCA1 and BRCA2 there are other genes, like RAD51C, that are associated with risk. We don't know as much about these genes though. |
| Christina Lizaso @btrfly12 RRSOs = Risk-reducing salpingo-oophorectomy = high risk but not cancer yet removal of ovaries and fallopian tubes #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @womenofteal @gyncsm #gyncsm The BRCA genes are involved in maintaining genomic stability. They repair our DNA. When they are mutated or lost, we have genomic INstability. That leads to cancer. |
| Dee Sparacio @womenofteal @ronny_drapkin @temkins I knew they were treated the same but did not know they were the same pathologically. Just assumed there was something different about them. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm: |
| Dee Sparacio @womenofteal RT @EMBOSU: Learn more about WISP here: Learn more about WISP here: https://t.co/rSkggrXgJb #gyncsm #gencsm #BRCA #LynchSyndrome #HereditaryCancer #previvors |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @michelerhee #gyncsm Great question. The risk of ovarian cancer is pretty low for average risk women. Sadly, we currently do not have a test for early detection. |
| GYN Cancer | #GYNCSM @gyncsm Moderator note... we are continuing on our last topic area: How will knowledge of where a majority of ovca originate impact women at increased risk? How might this research help in the development of an early detection test? What is the impact for women diagnosed w/ ovca?#gyncsm |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm |
| Erica Bednar @EMBOSU @michelerhee knowing/learning about your family history of cancer is an important piece of knowing if you may be in the higher vs average risk population. Family history of ovarian cancer can lead to recommendations of genetic counseling, testing, screening #gyncsm |
| Dee Sparacio @womenofteal @ronny_drapkin @gyncsm Your article in Nature https://t.co/vBVdQSVod6 about your research talks about TP53. How was that mutation important in your research? #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T6: This is the most exciting part. How does the FT matter!?! Lots of activity in this area. We are actively working with a company (nVision Medical) that has developed a modified hysteroscope that can sample the cells in the FT. It is like a pap smear of the FT. #gyncsm |
| Sarah Temkin @temkins @michelerhee @ronny_drapkin 5 years of oral contraceptive use decreases risk of #ovariancancer by 50%. #gyncsm. This is true for women at average and high risk of disease. #gyncsm. |
| Dee Sparacio @womenofteal RT @ronny_drapkin: T6: T6: This is the most exciting part. How does the FT matter!?! Lots of activity in this area. We are actively working with a company (nVision Medical) that has developed a modified hysteroscope that can sample the cells in the FT. It is like a pap smear of the FT. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @womenofteal @gyncsm #gyncsm TP53 is a tumor suppressor that is often called the 'Guardian of the Genome'. The loss of TP53 function early in the development of these cancers (along with BRCA) leads to the genomic instability that is the hallmark of HGSOC. |
| Lisa M Guzzardi, RN @LguzzardiM Womenโs cancers: how the discovery of #BRCA genes is driving current concepts of #cancer biology and therapeutics โฆ@nyulangoneโฉ #gyncsm #womenshealth #genetics #OvarianCancer #hereditarycancer https://t.co/t0O7vsTn7N |
| Sarah Temkin @temkins @michelerhee @ronny_drapkin 5 years of oral contraceptive use decreases risk of #ovariancancer by 50%. #gyncsm. This is true for women at average and high risk of disease. |
| Dee Sparacio @womenofteal @ronny_drapkin WOW ! Great to hear this development. #gyncsm |
| Sarah Temkin @temkins RT @EMBOSU: @michelerhee knowing/learning about your family history of cancer is an important piece of knowing if you may be in the higher vs average risk population. Family history of ovarian cancer can lead to recommendations of genetic counseling, testing, screening #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: @womenofteal @gyncsm #gyncsm TP53 is a tumor suppressor that is often called the 'Guardian of the Genome'. The loss of TP53 function early in the development of these cancers (along with BRCA) leads to the genomic instability that is the hallmark of HGSOC. |
| Lisa M Guzzardi, RN @LguzzardiM RT @ronny_drapkin: T6: T6: This is the most exciting part. How does the FT matter!?! Lots of activity in this area. We are actively working with a company (nVision Medical) that has developed a modified hysteroscope that can sample the cells in the FT. It is like a pap smear of the FT. #gyncsm |
| Dee Sparacio @womenofteal RT @LguzzardiM: Womenโs cancers: Womenโs cancers: how the discovery of #BRCA genes is driving current concepts of #cancer biology and therapeutics โฆ@nyulangoneโฉ #gyncsm #womenshealth #genetics #OvarianCancer #hereditarycancer https://t.co/t0O7vsTn7N |
| Lisa M Guzzardi, RN @LguzzardiM RT @ronny_drapkin: @womenofteal @gyncsm #gyncsm TP53 is a tumor suppressor that is often called the 'Guardian of the Genome'. The loss of TP53 function early in the development of these cancers (along with BRCA) leads to the genomic instability that is the hallmark of HGSOC. |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T6: the goal of such a device/method is to detect early FT cancers before they get to the ovary. We are currently testing it in women with pelvic masses but we are already planning to test it in BRCA mutation carriers. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: T6: T6: the goal of such a device/method is to detect early FT cancers before they get to the ovary. We are currently testing it in women with pelvic masses but we are already planning to test it in BRCA mutation carriers. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: T6: T6: This is the most exciting part. How does the FT matter!?! Lots of activity in this area. We are actively working with a company (nVision Medical) that has developed a modified hysteroscope that can sample the cells in the FT. It is like a pap smear of the FT. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Learning so much tonight. Thanks to our guest and thanks to all for joining in for more of an Ask the Expert type chat vs. broad open discussion. Hope you enjoyed it. We like to mix it up. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T6: Another approach relates to the concept of 'tissue proximal sampling'. This means that if we can get closer to the source of the cancer, perhaps we can detect it earlier. Efforts from @HopkinsMedicine are resulting in exciting results with a PapSeek test. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Learning so much tonight. Thanks to our guest and thanks to all for joining in for more of an Ask the Expert type chat vs. broad open discussion. Hope you enjoyed it. We like to mix it up. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin T6: PapSeek uses a regular endocervical pap brush to collect cells and determine if they harbor molecular defects of ovarian cancer. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: T6: T6: Another approach relates to the concept of 'tissue proximal sampling'. This means that if we can get closer to the source of the cancer, perhaps we can detect it earlier. Efforts from @HopkinsMedicine are resulting in exciting results with a PapSeek test. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: T6: T6: PapSeek uses a regular endocervical pap brush to collect cells and determine if they harbor molecular defects of ovarian cancer. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: T6: T6: Another approach relates to the concept of 'tissue proximal sampling'. This means that if we can get closer to the source of the cancer, perhaps we can detect it earlier. Efforts from @HopkinsMedicine are resulting in exciting results with a PapSeek test. #gyncsm |
 | drmalinowski @drmalinowski RT @temkins: A5: A5: For patients it's important to know that ovarian, fallopian tube and primary peritoneal high grade serous cancers are considered the same disease for the purpose of treatment #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: T6: T6: PapSeek uses a regular endocervical pap brush to collect cells and determine if they harbor molecular defects of ovarian cancer. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin #gyncsm We have a phase II clinical trial open at UPenn (and other place) looking at the utility of this device. Very exciting! |
| Dee Sparacio @womenofteal @ronny_drapkin This almost 14 yr HGSOC survivor thanks you for your research and appreciate you taking time to join our community tonight. #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: #gyncsm We have a phase II clinical trial open at UPenn (and other place) looking at the utility of this device. Very exciting! |
| Christina Lizaso @btrfly12 TIL: That things are starting to come together to make some great head-way in high-grade serous #ovariancancer. Every piece of the puzzle helps reveal new areas to study. #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @womenofteal #gyncsm Thank you for hosting this forum and giving me the opportunity to participate! |
| Dee Sparacio @womenofteal Agree! #gyncsm |
| Christina Lizaso @btrfly12 TIL: Tonight I also re-learned that I LOVE when we have researchers join the chat and that first time tweet chat guests can rock it out! Great job @ronny_drapkin #gyncsm |
| Erica Bednar @EMBOSU TIL the time it takes from STIC to development of HGSOC...exciting "window of opportunity" for ovarian cancer prevention and early detection, especially for women with inherited risks where the current risk reduction option= surgery...hopefully more options in future! #gyncsm |
| Dee Sparacio @womenofteal RT @EMBOSU: TIL the time it takes from STIC to development of HGSOC...exciting "window of opportunity" for ovarian cancer prevention and early detection, especially for women with inherited risks where the current risk reduction option= surgery...hopefully more options in future! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Save the Date! Join us on Wednesday, May 8th at 9pmET for our discussion on Supplements/Vitamins - Are they helpful? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Save the Date! Join us on Wednesday, May 8th at 9pmET for our discussion on Supplements/Vitamins - Are they helpful? #gyncsm |
| Dee Sparacio @womenofteal Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources . #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin I truly believe that efforts geared towards prevention and early detection stand the best chance of reducing mortality (and morbidity) from this disease. Now that we know where to look (the FT), I hope that process will be more rapid. #gyncsm |
| Christina Lizaso @btrfly12 Any last thoughts on "What is the impact for women already diagnosed with ovarian cancer?" #gyncsm |
| Christina Lizaso @btrfly12 RT @EMBOSU: TIL the time it takes from STIC to development of HGSOC...exciting "window of opportunity" for ovarian cancer prevention and early detection, especially for women with inherited risks where the current risk reduction option= surgery...hopefully more options in future! #gyncsm |
| Dee Sparacio @womenofteal RT @ronny_drapkin: I truly believe that efforts geared towards prevention and early detection stand the best chance of reducing mortality (and morbidity) from this disease. Now that we know where to look (the FT), I hope that process will be more rapid. #gyncsm |
| Sarah Temkin @temkins RT @ronny_drapkin: I truly believe that efforts geared towards prevention and early detection stand the best chance of reducing mortality (and morbidity) from this disease. Now that we know where to look (the FT), I hope that process will be more rapid. #gyncsm |
| Christina Lizaso @btrfly12 RT @ronny_drapkin: I truly believe that efforts geared towards prevention and early detection stand the best chance of reducing mortality (and morbidity) from this disease. Now that we know where to look (the FT), I hope that process will be more rapid. #gyncsm |
| Erica Bednar @EMBOSU Nice chatting with you all this evening! Thanks for hosting another great discussion @gyncsm and for sharing so much information @ronny_drapkin! #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin @btrfly12 #gyncsm Thank you @btrfly12 !!๐ |
| GYN Cancer | #GYNCSM @gyncsm Thanks again to all. As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| GYN Cancer | #GYNCSM @gyncsm Remember to check our blog https://t.co/oJ3xer6G8t for a transcript of the chat and resources. [ shout-out to @womenofteal for all her work on this! ] #gyncsm |
| Dee Sparacio @womenofteal @btrfly12 I think the impact may be on their daughters and sisters. Knowing where to look to catch the cancer early. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks again to all. As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Lisa M Guzzardi, RN @LguzzardiM TIL how promising research being spearheaded by @ronny_drapkinโs lab & others around the country offer much hope that we will have viable early detection #OvarianCancer methods available so that a cure becomes a reality & no longer progresses to late staged disease. #gyncsm |
| Dee Sparacio @womenofteal And a special thanks to @btrfly12 for keeping the chat flowing smoothly. You're the best! #gyncsm |
| Ronny Drapkin ๐ฎ๐ฑ ๐บ๐ธ @ronny_drapkin Really enjoyed my first Tweet Chat with #gyncsm. Thank you @btrfly12 and @womenofteal for the invitation! |
| GYN Cancer | #GYNCSM @gyncsm As always, we are grateful to the healthcare moderators of #gyncsm for their guidance, participation and support: @ShannonWestin @temkins @journeycancer @DrBeckerSchutte |
| GYN Cancer | #GYNCSM @gyncsm Have a wonderful evening all. Hope to see you on more 2nd Wednesdays at 9pmET for our #gyncsm discussions. |
| Dee Sparacio @womenofteal RT @gyncsm: Have a wonderful evening all. Hope to see you on more 2nd Wednesdays at 9pmET for our #gyncsm discussions. |
| GYN Cancer | #GYNCSM @gyncsm Thank you @ronny_drapkin for giving of your time to our #gyncsm chat and for all you do for the women impacted by gyn cancers. |
 | Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN #gyncsm sorry I missed the chat! I am on West Coast time instead of my usual East Coast time zone and got all messed up. Looks like it was a great chat, as usual! |
| GYN Cancer | #GYNCSM @gyncsm May 8th is also World #OvarianCancer Day! Learn more via @OvarianCancerDY #gyncsm |
#GynCSM content from Twitter.